Tuesday 20th November 2012
|Text too small?|
A2 Corp, which markets milk products with a protein variant claimed to have health benefits, is in talks with the New Zealand Stock Exchange about shifting its listing on the main board.
The company, currently listed on the alternative market, qualifies for listing on the NZX main board, and managing director Geoffrey Babidge says that is a more recognised market and can provide better transparency and investor protection, according to a presentation at today's annual meeting.
"A move to the NZX main board may provide greater liquidity and increase access to capital," Babidge said. "To this end, the company has commenced discussions with NZX regarding a move to the NZX main board."
Last month, the company completed a six-month strategic review and has embarked on plans to take control of its New Zealand marketing and accelerate its global expansion.
A2 recently entered into a Chinese distribution arrangement with China State Farm Holding Shanghai Company, a subsidiary of state-owned China National Agriculture Development Group Corp, as the exclusive distributor of its A2 brand infant formula.
The shares were unchanged at 65 cents, having surged 154 percent this year. That values the company at $393 million.
No comments yet
A2 Corp's Babidge, Mair take advantage of soaring price to sell 6M shares
A2 shares touch record-high as investors buy into growth story
A2 FY profit slips on cost of setting up UK joint venture, sales jump 51 percent as Australian shines
A2 first-half profit dented by UK joint venture, affirms annual earnings target of $11.2M
A2 to raise $20M in placement, big shareholders sell down
A2 Corp mulls capital structure in face of growth opportunities
A2 Corp, in talks to move to main board, halts shares pending statement
A2 Corp to take control of NZ marketing; enter North America, Europe
A2 Corp talks up Chinese infant formula market potential
A2 more than doubles FY profit as Australian sales surge